Sagefield Capital’s Corcept Therapeutics CORT Stock Holding History

Sagefield Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,150	Closed	-$82K	–	149
2021 Q4	$82K	Buy	+4,150	New	+$84.2K	0.04%	135

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sagefield Capital's CORT Position: Q1 2022 in Review

Sagefield Capital sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 4,150 shares — an estimated $82K sold.

Sagefield Capital first reported a position in CORT in Q4 2021 and held it in 1 quarter. The position peaked at $82K in Q4 2021. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

Sagefield Capital reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
Sagefield Capital sold 4,150 Corcept Therapeutics shares in Q1 2022, an estimated $82K.
Sagefield Capital first reported a position in Corcept Therapeutics in Q4 2021 and held it in 1 quarter.
Sagefield Capital's Corcept Therapeutics position peaked at $82K in Q4 2021.
228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Sagefield Capital's 13F filing for Q1 2022, filed 16 May 2022.